$26.71
5.36% yesterday
NYSE, Apr 23, 10:18 pm CET
ISIN
US4330001060
Symbol
HIMS

Hims & Hers Health Inc. Stock price

$26.71
-10.70 28.60% 1M
+5.33 24.93% 6M
+2.53 10.46% YTD
+14.38 116.63% 1Y
+21.89 454.15% 3Y
+16.83 170.34% 5Y
+16.91 172.55% 10Y
NYSE, Closing price Wed, Apr 23 2025
+1.36 5.36%
ISIN
US4330001060
Symbol
HIMS
Industry

Key metrics

Market capitalization $5.93b
Enterprise Value $5.65b
P/E (TTM) P/E ratio 49.94
EV/FCF (TTM) EV/FCF 28.46
EV/Sales (TTM) EV/Sales 3.82
P/S ratio (TTM) P/S ratio 4.02
P/B ratio (TTM) P/B ratio 12.37
Revenue growth (TTM) Revenue growth 69.33%
Revenue (TTM) Revenue $1.48b
EBIT (operating result TTM) EBIT $68.00m
Free Cash Flow (TTM) Free Cash Flow $198.33m
Cash position $300.25m
EPS (TTM) EPS $0.53
P/E forward 44.06
P/S forward 2.55
EV/Sales forward 2.42
Short interest 29.55%
Show more

Is Hims & Hers Health Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,783 stocks worldwide.

Hims & Hers Health Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Hims & Hers Health Inc. forecast:

6x Buy
38%
8x Hold
50%
2x Sell
13%

Analyst Opinions

16 Analysts have issued a Hims & Hers Health Inc. forecast:

Buy
38%
Hold
50%
Sell
13%

Financial data from Hims & Hers Health Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,477 1,477
69% 69%
100%
- Direct Costs 437 437
162% 162%
30%
1,039 1,039
47% 47%
70%
- Selling and Administrative Expenses 954 954
30% 30%
65%
- Research and Development Expense - -
-
-
85 85
422% 422%
6%
- Depreciation and Amortization 17 17
80% 80%
1%
EBIT (Operating Income) EBIT 68 68
289% 289%
5%
Net Profit 126 126
635% 635%
9%

In millions USD.

Don't miss a Thing! We will send you all news about Hims & Hers Health Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hims & Hers Health Inc. Stock News

Neutral
Seeking Alpha
about 22 hours ago
Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business, presenting a buying opportunity for long-term investors. The company is ramping up liraglutide manufacturing (an alternative to semaglutide) which will be able to recoup lost sales in its weight loss division after the FDA shortage of semaglutide ends. Hims trades at an appealing 18.1x EV/FY26 adjuste...
Negative
WSJ
about 24 hours ago
Hims, Keeps and other companies advertise topical finasteride with limited disclosures of side effects.
Positive
Seeking Alpha
3 days ago
Hims & Hers has shown explosive growth, with potential revenue of $2.5B in FY25, trading at a low 2.4x FY25 sales. Despite the high short interest and bear arguments, HIMS' data-driven personalization and high CAC are strategic for long-term disruption in healthcare. HIMS boasts $209M in free cash flow, a 14% FCF margin, and positive net income, making it a financially robust small-cap company.
More Hims & Hers Health Inc. News

Company Profile

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Head office United States
CEO Andrew Dudum
Employees 1,637
Founded 2017
Website www.forhims.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today